ViaCord Releases 250th Cord Blood Stem Cell Unit

  ViaCord Releases 250th Cord Blood Stem Cell Unit

   PerkinElmer’s Family Cord Blood and Tissue Preservation Business Reaches
                            Significant Milestone

Business Wire

WALTHAM, Mass. -- March 26, 2013

ViaCord, PerkinElmer’s family cord blood and tissue preservation business,
announced today the release of its 250^th umbilical cord blood stem cell unit
for use in medical treatments and clinical trials. For nearly 20 years,
ViaCord has released life-saving stem cells for disease therapies using a
proven method of processing and cryopreserving cord blood. To date, ViaCord
has released more units for use in medical treatments and clinical trialsthan
any other family bank.

“Reaching this milestone is a testament to our dedication to improving the
quality of life for families,” said Morey Kraus, Chief Scientific Officer,
ViaCord. “The benefits of cord blood banking are constantly evolving as
research, some of which ViaCord has been instrumental in supporting, continues
to expand the number of diseases treated. We are excited to continue to assist
families who have chosen to bank their newborns’ stem cells.”

Cord blood stem cells have been used in the treatment of nearly 80 diseases,
and more than 30,000 treatments have been conducted worldwide using cord blood
stem cells. ViaCord has released stem cells for the treatment of diseases
ranging from acute lymphoblastic leukemia, thalassemia major and sickle cell
disease. ViaCord’s 250th unit was used to treat a patient currently enrolled
in the Duke Translational Medicine Institute’s Cerebral Palsy Autologous Cord
Blood clinical trial conducted at Duke University Medical Center. In this
clinical trial, researchers are investigating the potential benefits of
autologous reinfusion of cord blood stem cells for children with cerebral
palsy.

ViaCord has preserved the umbilical cord stem cells of more than 300,000
newborns. ViaCord’s family cord blood and cord tissue services currently offer
expectant families the opportunity to bank their baby's umbilical cord blood
and tissue for potential medical use by the child or a related family member.
Through its Sibling Connection Program, ViaCord also provides the opportunity
for expectant parents, who have an eligible child in need of a transplant, to
receive cord blood and cord tissue stem collection, processing and five years
of storage, at no cost.

Please visit www.viacord.com for more information.

About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and
safety of people and the environment. The company reported revenue of
approximately $2.1 billion in 2012, has about 7,500 employees serving
customers in more than 150 countries, and is a component of the S&P 500 Index.
Additional information is available through 1-877-PKI-NYSE, or at
www.perkinelmer.com.

Contact:

Edelman (On behalf of PerkinElmer, Inc.)
Jen Reid, 404-460-8587
jen.reid@edelman.com
 
Press spacebar to pause and continue. Press esc to stop.